- $1.80bn
- $3.87bn
- $1.76bn
Brief: Endo To Report First Quarter 2025 Financial Results On May 7, 2025
Deals of the day-Mergers and acquisitions
Corrected: Deals of the day-Mergers and acquisitions
To Pay Endo $80.2 Million Termination Fee If Deal Is Terminated Under Certain Conditions
Drugmakers Mallinckrodt and Endo to merge in nearly $7 billion deal (updated)
Brief: Mallinckrodt And Endo To Combine To Create A Global, Scaled, Diversified Pharmaceuticals Leader
Brief: Drugmakers Mallinckrodt And Endo Are In Talks To Merge That Could Be Valued At About $7 Billion - Bloomberg News
Drugmakers Mallinckrodt, Endo in talks to merge, Bloomberg News reports (updated)
Drugmakers Mallinckrodt, Endo in talks to merge, Bloomberg News reports
Brief: Endo Announces Divestiture Of International Pharmaceuticals Business
Brief: Endo Announces Divestiture Of International Pharmaceuticals Business
Brief: Endo Announces Divestiture Of International Pharmaceuticals Business
Brief: FDA Warns Health Care Professionals Not To Use Epinephrine Nasal Solutions From BPI Labs And Endo USA
Brief: Endo Inc Issues Voluntary, Nationwide Recall Of Adrenalin® Chloride Solution Due To The Potential For Administration Errors
Brief: Endo Launches Adrenalin Ready-To-Use Premixed Bag, FDA-Approved, Manufacturer-Prepared Epinephrine Premixed I.V Bag
Brief: Endo Announces Agreement For Paladin Pharma To Commercialize Wynzora Cream In Canada
Brief: Endo Announces Agreement For Paladin Pharma To Commercialize Wynzora Cream In Canada
Brief: Endo Announces Successful Term Loan Repricing
Brief: Endo Inc - Completed Repricing Of Its $1.5 Billion Term Loan Due 2031